| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -5,418,671 | -3,821,039 |
| Depreciation expense | 46,767 | 36,143 |
| Stock-based compensation expense | -68 | -251 |
| Amortization of right-of-use asset | 75,105 | 54,105 |
| Write-off and impairment of property and equipment | 37,069 | 495 |
| Deferred offering costs | 101,170 | 0 |
| Prepaid expenses and other current assets | -463,187 | -291,460 |
| Other non-current assets | -26,530 | -13,093 |
| Accounts payable | 16,040 | -36,305 |
| Accrued expenses and other current liabilities | 256,506 | 223,387 |
| Non-cash interest expense for notes payable | 0 | 0 |
| Net cash used in operating activities | -4,598,705 | -3,238,912 |
| Proceeds from issuance of common stock and prefunded warrants | 3,846,692 | 3,846,692 |
| Issuance costs related to issuance of common stock | 464,670 | 464,670 |
| Payment of finance lease | 2,994 | 1,979 |
| Proceeds from issuance of notes payable, net of discounts of 287,580 | 0 | 0 |
| Repayment of notes payable | 0 | 0 |
| Proceeds from exercise of class d warrants | 0 | - |
| Net cash provided by financing activities | 3,379,028 | 3,380,043 |
| Purchase of property and equipment | 0 | 0 |
| Net cash used in investing activities | 0 | 0 |
| Increase in cash and cash equivalents | -1,219,677 | 141,131 |
| Cash and cash equivalents at beginning of period | 4,301,945 | - |
| Cash and cash equivalents at end of period | 3,082,268 | - |
Bluejay Diagnostics, Inc. (BJDX)
Bluejay Diagnostics, Inc. (BJDX)